Revium Rx.

EFFECT effective

Revium Rx's S-1 registration statement became effective on January 30, 2026, following an S-1/A amendment filed on January 28, 2026. The filing includes exhibits and signatures but no new substantive changes beyond the effectiveness.

S-1/A amended

Revium Rx filed an amended S-1 registration statement (Amendment No. 5) as an exhibits-only filing, updating disclosure related to its proposed initial public offering (IPO). The filing includes updated exhibits and signatures but omits prior prospectus sections. The company, formerly known as Revium Recovery Inc., operates in the pharmaceutical sector with licensing agreements for drug development. The IPO involves 1,562,500 units (2 shares + 1 warrant per unit) at $3.20/unit, with a separate resale offering of 37.6 million shares by existing shareholders.

S-1/A amended

Revium Rx. is conducting an initial public offering (IPO) of up to 1,562,500 units, each consisting of two shares of common stock and one warrant to purchase an additional share. The company is also registering up to 37,625,790 shares of common stock for resale by existing shareholders. The primary offering is priced at $3.20 per unit, while the resale offering will occur at a fixed price of $1.00 per share, potentially impacting the primary offering's success. The filing includes two prospectuses: one for the public offering and one for the resale offering, with differences in sections like Selling Stockholders and Plan of Distribution.

S-1/A amended

Price $3.20 · 1,562,500 shares · Gross proceeds $5,000,000

Revium Rx. is conducting an initial public offering (IPO) registering up to 1,562,500 Units (each containing two shares of common stock and one warrant) and a resale offering of 37,625,790 shares of common stock. The Primary Offering is priced at $3.20 per Unit, while the Resale Offering is set at a fixed $1.00 per share, potentially affecting the primary offering's success. The company remains unlisted on a national exchange, with uncertainty around OTCQB quotation.

S-1/A amended

Revium Rx is conducting an initial public offering (IPO) of 1,562,500 units, each consisting of two shares of common stock and a warrant to purchase one share. The company also registered up to 37,625,790 shares for resale by selling stockholders. The offering is self-underwritten, with a fixed price of $3.20 per unit for the primary offering and $1.00 per share for the resale offering. The filing highlights potential conflicts between the primary and resale offerings due to the lower resale price and risks related to stock valuation and liquidity.

S-1/A amended

Revium Rx. filed an S-1/A amendment to its initial public offering (IPO) registration, detailing a self-underwritten public offering of 1,562,500 units (each containing two shares of common stock and a warrant) and a resale offering of up to 37,625,790 shares by selling stockholders. The filing includes updated prospectus sections, including changes to the Use of Proceeds, Selling Stockholders, and Plan of Distribution, while maintaining similar securities structure and pricing terms.

S-1 filed

Price $3.20 · 1,562,500 shares · Gross proceeds $5,000,000

Revium Rx is conducting a self-underwritten initial public offering (IPO) of 1,562,500 units, each consisting of two shares of common stock and a warrant. Additionally, up to 37,625,790 shares of common stock are being registered for resale by selling stockholders. The company, formerly known as Revium Recovery Inc., has a history of name changes and mergers, including a recent reincorporation from Delaware to Nevada. The offering price is fixed at $3.20 per unit until the stock is quoted on a higher OTC marketplace or listed on a national exchange.